Hussman Strategic Advisors Inc. Grows Stake in ICU Medical, Inc. (NASDAQ:ICUI)

Hussman Strategic Advisors Inc. boosted its position in ICU Medical, Inc. (NASDAQ:ICUI) by 66.7% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,000 shares of the medical instruments supplier’s stock after purchasing an additional 8,400 shares during the period. Hussman Strategic Advisors Inc. owned about 0.09% of ICU Medical worth $2,916,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of ICUI. Harvest Fund Management Co. Ltd acquired a new stake in shares of ICU Medical during the fourth quarter worth $33,000. Quarry LP boosted its holdings in ICU Medical by 764.3% in the fourth quarter. Quarry LP now owns 242 shares of the medical instruments supplier’s stock valued at $38,000 after acquiring an additional 214 shares during the last quarter. Murphy & Mullick Capital Management Corp purchased a new position in ICU Medical in the fourth quarter valued at about $52,000. Russell Investments Group Ltd. raised its position in ICU Medical by 88.8% in the fourth quarter. Russell Investments Group Ltd. now owns 638 shares of the medical instruments supplier’s stock valued at $99,000 after purchasing an additional 300 shares during the period. Finally, Sterling Capital Management LLC raised its position in ICU Medical by 813.5% in the fourth quarter. Sterling Capital Management LLC now owns 676 shares of the medical instruments supplier’s stock valued at $105,000 after purchasing an additional 602 shares during the period. Institutional investors and hedge funds own 96.10% of the company’s stock.

ICU Medical Stock Down 0.5%

Shares of ICU Medical stock traded down $0.58 on Friday, hitting $124.15. 13,051 shares of the company traded hands, compared to its average volume of 256,064. The company has a 50-day moving average price of $132.89 and a 200 day moving average price of $144.20. The company has a market cap of $3.06 billion, a PE ratio of -32.40 and a beta of 0.87. The company has a quick ratio of 1.52, a current ratio of 2.59 and a debt-to-equity ratio of 0.75. ICU Medical, Inc. has a 12-month low of $117.92 and a 12-month high of $196.26.

ICU Medical (NASDAQ:ICUI) last issued its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.72 earnings per share for the quarter, topping the consensus estimate of $1.23 by $0.49. The firm had revenue of $599.49 million for the quarter, compared to analysts’ expectations of $574.15 million. ICU Medical had a negative net margin of 3.87% and a positive return on equity of 6.75%. The company’s quarterly revenue was up 6.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.96 earnings per share. Sell-side analysts predict that ICU Medical, Inc. will post 4.11 earnings per share for the current year.

Insider Activity

In other news, COO Christian B. Voigtlander sold 4,985 shares of the firm’s stock in a transaction that occurred on Wednesday, May 28th. The shares were sold at an average price of $128.50, for a total transaction of $640,572.50. Following the transaction, the chief operating officer directly owned 6,088 shares of the company’s stock, valued at approximately $782,308. This trade represents a 45.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director David C. Greenberg sold 1,942 shares of ICU Medical stock in a transaction that occurred on Tuesday, May 13th. The shares were sold at an average price of $143.66, for a total transaction of $278,987.72. Following the completion of the transaction, the director directly owned 6,760 shares in the company, valued at $971,141.60. This trade represents a 22.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 36,097 shares of company stock valued at $4,860,156. Company insiders own 1.50% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have commented on the company. Needham & Company LLC reissued a “hold” rating on shares of ICU Medical in a research report on Tuesday, April 8th. Wall Street Zen raised ICU Medical from a “hold” rating to a “buy” rating in a research report on Sunday, May 18th. Raymond James Financial dropped their target price on ICU Medical from $197.00 to $187.00 and set a “strong-buy” rating on the stock in a research report on Friday, May 9th. Finally, KeyCorp dropped their target price on ICU Medical from $209.00 to $191.00 and set an “overweight” rating on the stock in a research report on Monday, April 21st. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, ICU Medical has a consensus rating of “Buy” and a consensus target price of $192.67.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.